Melanoma Clinical Trials in Texas

Showing 81-100 of 114 trials

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994

This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + Sorafenib or DTIC + Placebo.

CancerMelanoma

Bayer101 participantsStarted Apr 2005

Tucson, Arizona, United States • Aurora, Colorado, United States • Lakeland, Florida, United States +11 more locations

COMPLETEDPHASE1127 miles

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

NCT02608034

This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF where the participant has no acceptable standard treatment options.

Metastatic Melanoma, BRAF V600 Mutation Positive

Genentech, Inc.32 participantsStarted May 2016

Dallas, Texas, United States • Haifa, Israel • Jerusalem, Israel +8 more locations

PreviousPage 5 of 6Next

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Melanoma Trials in Other Cities

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Other Conditions in Texas